Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney collecting ducts, promoting water reabsorption. It also stimulates V2 receptors on endothelial cells, causing release of factor VIII and von Willebrand factor, which improves blood clotting.

The dose of Minirin is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function and response. Only a qualified health professional should determine the appropriate regimen.

Safety data for Minirin in pregnancy and lactation are limited. The prescribing physician should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant or nursing should discuss use with their healthcare provider.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older antidiuretic agents such as chlorpropamide, desmopressin offers a more selective V2‑receptor profile, resulting in fewer systemic side effects and a longer duration of action. It is also used for haemostatic purposes, a benefit not shared by many traditional diuretics.

Minirin nasal spray should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and discard any product that appears discoloured or has an altered smell.

Minirin is supplied as a metered‑dose nasal spray. The patient or caregiver primes the device, then gently inserts the tip into one nostril and actuates the prescribed number of sprays, usually while the head is tilted slightly forward. Instructions from the prescriber must be followed precisely.

The most serious adverse events are severe hyponatraemia, water intoxication, seizures, and cerebral oedema. These can occur especially when fluid intake is excessive or when the drug is combined with other antidiuretic agents. Prompt medical attention is required if symptoms such as headache, confusion or vomiting develop.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin, uncontrolled hyponatraemia, severe renal impairment, or those taking other potent antidiuretic medications without close monitoring. Clinicians should also avoid use in individuals with unstable cardiovascular disease unless benefits clearly outweigh risks.